137 related articles for article (PubMed ID: 35870420)
21. Clinical Implications of the Progression-Free Survival Endpoint for Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
Kaklamani VG
Oncologist; 2016 Aug; 21(8):922-30. PubMed ID: 27256875
[TBL] [Abstract][Full Text] [Related]
22. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
Vrdoljak E; Marschner N; Zielinski C; Gligorov J; Cortes J; Puglisi F; Aapro M; Fallowfield L; Fontana A; Inbar M; Kahan Z; Welt A; Lévy C; Brain E; Pivot X; Putzu C; González Martín A; de Ducla S; Easton V; von Minckwitz G
Ann Oncol; 2016 Nov; 27(11):2046-2052. PubMed ID: 27502725
[TBL] [Abstract][Full Text] [Related]
23. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry.
Müller V; Nabieva N; Häberle L; Taran FA; Hartkopf AD; Volz B; Overkamp F; Brandl AL; Kolberg HC; Hadji P; Tesch H; Ettl J; Lux MP; Lüftner D; Belleville E; Fasching PA; Janni W; Beckmann MW; Wimberger P; Hielscher C; Fehm TN; Brucker SY; Wallwiener D; Schneeweiss A; Wallwiener M
Breast; 2018 Feb; 37():154-160. PubMed ID: 29237546
[TBL] [Abstract][Full Text] [Related]
24. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis.
Adunlin G; Cyrus JW; Dranitsaris G
Breast Cancer Res Treat; 2015 Dec; 154(3):591-608. PubMed ID: 26596731
[TBL] [Abstract][Full Text] [Related]
25. Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States.
Zanotti G; Hunger M; Perkins JJ; Horblyuk R; Martin M
BMC Cancer; 2017 Jun; 17(1):393. PubMed ID: 28578656
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
27. Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life.
De Luca R; Profita G; Cicero G
Onco Targets Ther; 2019; 12():1621-1627. PubMed ID: 30881017
[TBL] [Abstract][Full Text] [Related]
28. Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients.
Chen IC; Hu FC; Lin CH; Huang SM; Chang DY; Cheng AL; Lu YS
Breast; 2021 Oct; 59():211-220. PubMed ID: 34298300
[TBL] [Abstract][Full Text] [Related]
29. Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Tremblay G
Breast Cancer (Dove Med Press); 2018; 10():69-78. PubMed ID: 29765247
[TBL] [Abstract][Full Text] [Related]
30. Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of 24 randomized trials.
Liu L; Chen F; Zhao J; Yu H
Bull Cancer; 2016 Apr; 103(4):336-44. PubMed ID: 26874974
[TBL] [Abstract][Full Text] [Related]
31. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
32. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Cabel L; Carton M; Cheaib B; Pierga JY; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Desmoulins I; Lefeuvre C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Perrocheau G; Piot I; Pérol D; Simon G; Lerebours F
Breast Cancer Res Treat; 2019 Jan; 173(2):397-406. PubMed ID: 30357526
[TBL] [Abstract][Full Text] [Related]
33. Re-imagining metastatic breast cancer care delivery: a patient-partnered qualitative study.
Roberson ML; Henricks A; Woods J; Glenn L; Maues J; James D; Reid S
Support Care Cancer; 2023 Nov; 31(12):735. PubMed ID: 38055111
[TBL] [Abstract][Full Text] [Related]
34. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
Montero AJ; Avancha K; Glück S; Lopes G
Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
[TBL] [Abstract][Full Text] [Related]
35. Everolimus-Related Pneumonitis in Patients with Metastatic Breast Cancer: Incidence, Radiographic Patterns, and Relevance to Clinical Outcome.
Gong C; Xiao Q; Li Y; Gu Y; Zhang J; Wang L; Cao J; Tao Z; Zhao Y; Xie Y; Hu X; Wang B
Oncologist; 2021 Apr; 26(4):e580-e587. PubMed ID: 33191524
[TBL] [Abstract][Full Text] [Related]
36. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
37. Significance of Patient-Reported Outcomes for Metastatic Breast Cancer Patients.
Hillebrand LE; Söling U; Marschner N
Oncol Res Treat; 2022; 45(7-8):423-429. PubMed ID: 34999590
[TBL] [Abstract][Full Text] [Related]
38. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
Wood R; Mitra D; de Courcy J; Iyer S
Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
[TBL] [Abstract][Full Text] [Related]
39. Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y; Lok SW; Gibbs P; De Boer R; Yeo B; Greenberg S; Barnett F; Knott L; Richardson G; Wong R; Nottage M; Collins IM; Torres J; Lombard J; Johns J; Harold M; Malik L
Breast Cancer Res Treat; 2020 Nov; 184(1):87-95. PubMed ID: 32779037
[TBL] [Abstract][Full Text] [Related]
40. Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.
Miyashita M; Hattori M; Takano T; Toyama T; Iwata H
Breast Cancer; 2020 May; 27(3):347-354. PubMed ID: 31974704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
